Skip to main content
. 2018 Apr 23;19(4):1262. doi: 10.3390/ijms19041262

Figure 3.

Figure 3

Figure 3

Effect of erythropoietin β (Epo), LFM-A13 (LFM), and their combinations on intracellular pathway and apoptosis. (a) Representative flow cytometry dot plots for Annexin V–FITC (fluorescein isothiocyanate) assay of DLD-1 and HT-29 cells incubated with Epo (Epo100, 100 IU/mL) and LFM-A13 (LFM100, 100 μM) for 48 h (mean ± SD; n = 3). The live cells appear at the lower left corner in the plots; the early apoptotic cells appear at the lower right corner; the necrotic cells appear at the upper left corner; the dead cells appear at the upper right corner. Left panel: The percentage of apoptotic DLD-1 cells incubated with Epo and LFM-A13 is shown in the bar diagram as mean ± SD (n = 3). Right panel: The percentage of apoptotic HT-29 cells incubated with Epo and LFM-A13 is shown in the bar diagram as mean ± SD (n = 3); * p < 0.05 (vs. Con), ** p < 0.01 (vs. Con), *** p < 0.001 (vs. Con); ^ p < 0.05 (vs. Epo), ^^^ p < 0.001 (vs. Epo); # p < 0.05 (vs. LFM-A13), ### p < 0.001 (vs. LFM-A13). (b) Representative dot plots presenting the loss of mitochondrial membrane potential (MMP) in DLD-1 and HT-29 cells incubated with Epo (Epo100, 100 IU/mL) and LFM-A13 (LFM100, 100 μM) for 48 h (mean ± SD; n = 3). Cells with normal MMP are shown on the right side of the plots, cells with decreased MMP on the left side of the plots. The graphs show the percent of cells with decreased mitochondrial membrane potential in DLD-1 (left panel) and HT-29 cells (right panel).